Zenith Drugs Ltd (ZENITHDRUG) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Zenith Drugs Ltd on NSE and BSE, with an AI summary of each filing.
Zenith Drugs Limited has informed the Exchange about securing a tender awarded Rajasthan Medical Services Corporation Limited.
Others (Uncategorized) · 04 Nov 2026, 6:08 pm
Zenith Drugs Secures INR 1.24 Cr Order from RMSCL Zenith Drugs Limited has been awarded a tender under a rate contract by Rajasthan Medical Services Corporation Limited (RMSCL) for the supply of drugs and medicines, per a Letter of Acceptance dated 4th Nov'26. The contract entails supplying 2,26,944 units of Pregabalin Capsules IP 75 mg (10x10 capsules) at an accepted rate of ₹54.70 per packing unit. The total contract value stands at ₹1.24 Cr inclusive of GST, awarded in the normal course of business.
Zenith Drugs Limited has informed the Exchange about securing a tender awarded by Uttar Pradesh Medical Supplies Corporation Limited.
Others (Uncategorized) · 30 Oct 2026, 8:37 pm
Zenith Drugs Secures INR 72.66 Lakh Tender from UP Medical Supplies Zenith Drugs Limited has secured a supply contract from Uttar Pradesh Medical Supplies Corporation Limited, a Government of Uttar Pradesh undertaking. Under the tender, the company will supply 11,87,160 units of Betamethasone Valerate 0.1% W/W Cream (15 gm tube) out of a total tender volume of 59,35,800 units. The accepted rate stands at ₹6.1202 per unit, bringing the total order value to ₹72,65,657 (inclusive of GST). The domestic order falls within the regular course of business.
Zenith Drugs Limited has informed the Exchange regarding Outcome of Board Meeting held on October 13, 2026.
Outcome · 13 Oct 2026, 8:13 pm
Zenith Drugs Approves ₹13.75 Crore Land and Building Asset Sale Zenith Drugs Limited’s board approved the sale of its 5-hectare land and building in Mohana, Indore, to ACE Engineering & Chemicals Private Limited for ₹13.75 crore on an arm's-length basis. The asset contributed 0% to revenue but represents ~18.57% of company net worth as per FY25-26 audited financials. The sale deed is proposed to be executed by 20th Oct'26, with full consideration and transaction completion expected on or before 20th Nov'26. The disposal does not involve promoter entities or a slump sale.
Zenith Drugs Limited has informed the Exchange about securing a tender awarded by Haryana Medical Services Corporation Limited.
Others (Uncategorized) · 10 Oct 2026, 6:08 pm
Zenith Drugs Secures Two-Year Medicine Supply Contract from HMSCL Zenith Drugs Limited received a Letter of Acceptance from Haryana Medical Services Corporation Limited on 10th Oct'26 for Tender No. 384. The two-year contract entails supplying Group-B medicines, specifically Cough Syrup (100 ml bottles containing Ambroxol, Terbutaline Sulphate, Guaiphenesin, and Menthol), to Government of Haryana hospitals under the Directorate General of Health Services. The accepted rate is ₹11.15 per unit, inclusive of all taxes. Awarded in the normal course of business, the contract is expected to enhance operational performance.
Zenith Drugs Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on September 29, 2026. Further, the company has informed the Exchange regarding voting results.
Annual General Meeting · 01 Oct 2026, 12:55 am
Zenith Drugs Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 29, 2026
Annual General Meeting · 29 Sept 2026, 7:22 pm
Zenith Drugs Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 29, 2026
Annual General Meeting · 05 Sept 2026, 6:43 pm
Zenith Drugs Limited has informed the Exchange regarding Outcome of Board Meeting held on September 05, 2026.
Outcome · 05 Sept 2026, 6:37 pm
Zenith Drugs Schedules 26th AGM and Reappoints Secretarial Auditor for FY27 Zenith Drugs Limited’s Board of Directors approved convening the company's 26th Annual General Meeting on 29th Sep'26 via Video Conferencing/OAVM. Additionally, the Board approved the re-appointment of M/s. Agrawal & Maheshwari, Practicing Company Secretaries, as the Secretarial Auditor for FY27. Ms. Geetika Agrawal, Partner at Agrawal & Maheshwari, has been appointed as the Scrutinizer to oversee the e-voting process for the upcoming AGM.
Zenith Drugs Limited has informed the Exchange regarding allotment of 1609050 share warrants pursuant to Preferential Issue at its meeting held on August 26, 2026
Others (Uncategorized) · 26 Aug 2026, 7:20 pm
Zenith Drugs Board Approves Warrant Allotment and Director Re-designation Zenith Drugs' board, on Aug 26, 2026, approved two key actions. First, Mr. Ajay Singh Dassundi was re-designated from Executive to Non-Executive (Non-Independent) Director, effective Aug 27, 2026. Second, the board allotted 16,09,050 convertible warrants to the Promoter Category on a preferential basis. This follows receipt of Rs. 1.75 crore, representing 25% of the total consideration. Upon full conversion, promoter group holding would increase from 64.08% to 67.16%. The warrants are convertible into equity shares at Rs. 43.50 each.
Zenith Drugs Limited has informed the Exchange regarding Outcome of Board Meeting held on August 26, 2026.
Outcome · 26 Aug 2026, 6:41 pm
Zenith Drugs Approves Warrant Allotment & Director Re-designation On 26 Aug'26, Zenith Drugs' board approved the allotment of 16,09,050 convertible warrants to the Promoter group at an issue price of ₹43.50 per warrant. The company received ₹1.75 crore, representing 25% of the aggregate consideration. Upon full conversion, this will raise ₹7.00 crore and increase promoter holding from 64.08% to 67.16%. Additionally, the board approved the re-designation of Mr. Ajay Singh Dassundi from Executive Director to Non-Executive (Non-Independent) Director, effective 27 Aug'26.
Zenith Drugs Limited has informed the Exchange regarding Outcome of Board Meeting held on August 26, 2026.
Outcome · 26 Aug 2026, 6:40 pm
Zenith Drugs Approves Warrant Allotment and Director Re-designation On 26 Aug'26, Zenith Drugs' board approved allotting 16,09,050 convertible warrants to the promoter group on a preferential basis. The company received Rs. 1.75 Cr, representing 25% of the aggregate consideration. The warrants have an issue price of Rs. 43.50 each and can be converted into equity shares within 18 months. This allotment will increase the promoter group's holding from 64.08% to 67.16% post-conversion. The board also approved the re-designation of Mr. Ajay Singh Dassundi from Executive to Non-Executive (Non-Independent) Director.
Zenith Drugs Limited has submitted the Exchange a copy Srutinizers report of Extraordinary General Meeting held on July 23, 2026. Further, the company has informed the Exchange regarding voting results.
Annual General Meeting · 25 Jul 2026, 8:54 pm
Zenith Drugs Shareholders Approve Preferential Warrant Issue to Promoters Zenith Drugs shareholders approved a special resolution for the issuance of up to 1,609,050 fully convertible warrants to promoters on a private placement basis. The resolution was passed with requisite majority at the Extraordinary General Meeting held on 23 Jul'26. The combined e-voting results showed 510,400 votes (100% of votes cast in favour) supporting the resolution, with 98.90% from remote e-voting and 1.10% during the EGM. Only 1,600 votes were cast against the proposal, representing 100% of votes cast against.
Zenith Drugs Limited has informed the Exchange regarding Proceedings of Extraordinary General Meeting held on July 23, 2026.
Annual General Meeting · 23 Jul 2026, 9:25 pm
Zenith Drugs to Issue 16.09 Lakh Convertible Warrants to Promoters Zenith Drugs Limited (NSE: ZENITHDRUG) announced that at its Extraordinary General Meeting on 23 Jul'26, shareholders approved the issuance of up to 1,609,050 fully convertible warrants. The warrants will be issued on a preferential allotment basis via private placement to individuals in the promoter category. The company stated the issuance is for the purpose of fund raising. The special resolution for the approval was transacted and passed during the meeting, which was held via video conferencing.
Zenith Drugs Limited has informed the Exchange regarding Corrigendum to Notice of Extra Ordinary General Meeting to be held on July 23, 2026
Extra Ordinary General Meeting · 11 Jul 2026, 12:40 am
Zenith Drugs Announces Corrigendum for EGM on Preferential Warrant Issue Zenith Drugs has issued a corrigendum for its EGM on 23rd Jul'26, which seeks approval for a preferential issue of fully convertible warrants. The amendments were prompted by NSE observations and do not change the core proposal. Key changes include revised disclosures on shareholding patterns, loan terms, and valuation reports. Post-conversion, the promoter group's holding is projected to increase from 69.98% to 72.55%, while public shareholding will decrease from 30.02% to 27.45%. The preferential issue is not expected to result in a change of control.
Zenith Drugs Limited has informed the Exchange regarding Notice of Extraordinary General Meeting to be held on July 23, 2026
Annual General Meeting · 30 Jun 2026, 10:44 pm
Zenith Drugs to Issue 1.6M Warrants to Promoters via Preferential Allotment Zenith Drugs will hold an EGM on 23 Jul'26 to approve a preferential issue of up to 1,609,050 fully convertible warrants to its promoters. The issue, priced at ₹43.50 per warrant, aims to raise ₹7.00 crores. Proceeds will be used for repayment of an HDFC Term Loan (₹4.00 Cr) and working capital requirements (₹3.00 Cr). Upon full conversion, the promoter group's shareholding is projected to increase from 69.98% to 72.55%. The warrants are convertible into equity within 18 months from allotment.
Zenith Drugs Limited has informed the Exchange regarding Outcome of Board Meeting held on Jun 26, 2026.
Outcome · 26 Jun 2026, 11:55 pm
Zenith Drugs to Raise ₹7 Cr via Preferential Warrant Issue to Promoters Zenith Drugs' board approved on Jun 26, 2026, a preferential issue of 16,09,050 convertible warrants to three promoter entities to raise up to ₹7 Cr. The issue price is set at ₹43.50 per warrant, convertible into one equity share within 18 months. This fundraising is subject to shareholder approval at an EGM scheduled for Jul 23, 2026. The promoter group's aggregate shareholding will increase from 64.08% to 67.18% post-conversion. The funds are intended for corporate purposes and to strengthen the financial position.